Please use this identifier to cite or link to this item:
|Title:||A rapid HPLC method for the quantification of 3,5,4′-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study|
|Authors:||Lin, H.-S. |
|Citation:||Lin, H.-S., Ho, P.C. (2009-02-20). A rapid HPLC method for the quantification of 3,5,4′-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 49 (2) : 387-392. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jpba.2008.10.042|
|Abstract:||A rapid HPLC-UV method had been developed and validated to quantify 3,5,4′-trimethoxy-trans-stilbene (TMS), a naturally occurring and pharmacologically active analog of resveratrol in rat plasma. The samples were mixed with three volumes of acetonitrile to precipitate protein. Chromatographic separation was achieved on a RP-HPLC column (Agilent ZORBAX Eclipse Plus C18: 250 mm × 4.6 mm i.d., 5 μm), which was protected by a guard column (Agilent ZORBAX Eclipse Plus C18: 12.5 mm × 4.6 mm i.d., 5 μm) through isocratic delivery of a mobile phase of acetonitrile: water (75:25, v/v) at a flow rate of 1.2 ml/min. The assay was executed at 30 °C and the UV absorbance at 320 nm was monitored. The retention time of TMS and trans-stilbene (internal standard) was 6.5 and 8.3 min, respectively. The calibration curve was linear within the range of 15-1000 ng/ml (R2 > 0.998) and 15 ng/ml was the lower LOQ. The intra- and inter-day precisions were good and the RSD was all lower than 7.3%. The mean absolute recovery of TMS in plasma ranged from 99.2 to 104.1%. This HPLC method had been successfully applied to study the pharmacokinetics of TMS, which was fully dissolved with hydroxypropyl-β-cyclodextrin (HP-β-CyD). In comparison with resveratrol, TMS had greater plasma exposure, longer elimination half-life and lower clearance. As TMS had superior pharmacokinetic characteristics, its potential as a preventive or therapeutic agent in resveratrol-effective conditions or diseases should be considered. © 2008 Elsevier B.V. All rights reserved.|
|Source Title:||Journal of Pharmaceutical and Biomedical Analysis|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 14, 2019
WEB OF SCIENCETM
checked on Feb 5, 2019
checked on Jan 25, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.